ClinicalTrials.gg
CompletedNCT02273726Updated Oct 29, 2021Results posted

Study to Evaluate the Efficacy and Safety of Roxadustat in the Treatment of Anemia in Participants With ESRD on Stable Dialysis

A Phase 3 interventional study of Epoetin Alfa and Roxadustat in CKD Anemia in Stable Dialysis Patients, sponsored by FibroGen. Completed at 76 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-10-29.

Sponsored by FibroGen · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
741
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 43 studies testing roxadustat in Anemia — 2 open to participants now, 4 under way, 3 of them phase 3. roxadustat · Anemia.

Enrollment
6th of 43
741 · median 154
Started
2015
with 2 others
Phase 3
25 of 43
1 open now
Registered
15th of 43
by date
Lead sponsor
20 of 43
FibroGen

Among the 43 studies testing roxadustat in Anemia, this one is the 6th largest by enrollment, is one of 3 that started in 2015, is one of 25 in phase 3, and was the 15th registered.

Anemia

1,810 studies on the registry are indexed under Anemia; 215 are open to participants now.

Browse Anemia studies →

Open to participants now

2 of the 43 studies testing roxadustat in Anemia are open now. Recruiting first, the newest first:

All 2 open studies →

About roxadustat

roxadustat: first EMA approval 2021. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 122 Anemia studies recruiting now, 67 (55%) set no upper age limit and 37 (30%) stop at 75 or younger; 34 take children under 18; 23 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies testing roxadustat in Anemia, or all of them as a file.
02

Study summary

The primary objective of this study is to evaluate the efficacy and safety of roxadustat compared with active control (epoetin alfa) for the maintenance treatment of anemia in participants with ESRD on dialysis.

Read the detailed description

This study will consist of three study periods as follows:

  1. Screening Period of up to 6 weeks (8 weeks if on Mircera)
  2. Treatment Period: a minimum of 52 weeks, a maximum of up to 3 years from the date last participant is randomized. Minimum study duration for participants enrolled under Protocol Amendment 1 or 2 may be less than 52 weeks
  3. A Follow-up period of 4 weeks.

Participants will be randomized in a 1:1 ratio to receive either roxadustat or epoetin alfa (active control) in an open-label manner.

03

Conditions studied

  • CKD Anemia in Stable Dialysis Patients

Keywords

  • Anemia
  • Chronic Kidney Disease
  • Dialysis
  • hemodialysis
  • peritoneal dialysis
  • hemoglobin
  • End stage renal disease
  • Stable Dialysis
  • erythropoietins
  • erythropoiesis stimulating agent
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Receiving dialysis for ESRD for ≥3 months. Incident dialysis participants (under Amendment 1 and 2) receiving dialysis for ESRD for ≥ 2 weeks but ≤ 4 months at the time of randomization
  • Participants must be on ESA for ≥ 8 weeks prior to screening; incident dialysis participants must be on ESA for ≥ 4 weeks prior to screening.
  • Mean of the 3 most recent central lab values during the Screening Period must be ≥ 9.0 g/dL and ≤ 12.0 g/dL (for incident dialysis participants, mean of the 2 most recent Hb values must be ≥ 8.5 g/dL and ≤ 12.0 g/dL); with an absolute difference of ≤ 1.3 g/dL between the highest and the lowest value. Samples are obtained at least 4 days apart (2 days under Amendment 2) and the last Hb value must be within 10 days prior to the randomization visit
  • Participants with ferritin level ≥ 100 nanograms (ng)/milliliter (mL) (\<100 ng/mL under Amendment 2) or transferrin saturation (TSAT) ≥ 20% (\<20% under Amendment 2) at screening may qualify upon receiving iron supplement (per local standard of care)
  • Participants with a serum folate and Vitamin B12 ≥ lower limit of normal (LLN) (\< LLN under Amendment 2) at screening may qualify upon receiving supplement (per local standard of care)
  • Participant's (ALT) and aspartate aminotransferase (AST) are ≤3x the (ULN), and total (TBL) is ≤1.5x ULN at screening
  • Participant's body weight is 45 kilograms (kg) to 160 kg.

Exclusion criteria

Exclusion Criteria:

  • Participant has received an red blood cell (RBC) transfusion within 8 weeks (4 weeks under Amendment 2) prior to randomization
  • Participant has known history of myelodysplastic syndrome or multiple myeloma
  • Participant has known inherited disease such as thalassemia or sickle cell anemia or other known causes for anemia other than chronic kidney disease.
  • Participant has known hemosiderosis, hemochromatosis, coagulation disorder,or hypercoagulable condition
  • Participant has known chronic inflammatory disease that could cause anemia
  • Participant has anticipated surgery that is expected to cause blood loss
  • Participant has known gastrointestinal bleeding
  • Participant has history of chronic liver disease (for example, chronic infectious hepatitis,chronic auto-immune liver disease,cirrhosis, or fibrosis of the liver)
  • Participant with (NYHA) Class III or IV congestive heart failure
  • Participant has had a heart attack, stroke, seizure, or a thrombotic/thromboembolic event (for example, deep vein thrombosis or pulmonary embolism) within 12 weeks prior to participating in the study
  • Participant has uncontrolled high blood pressure within 2 weeks prior to participating in the study
  • Participant has a history of , except for the following: cancers determined to be cured or in remission for ≥2 years, curatively resected basal cell or squamous cell skin cancers, cervical cancer in situ, or resected colonic polyps.)
  • Participant is positive for (HIV), surface antigen, or anti- virus antibody
  • Participant with prior organ transplant who experience rejection within 6 months or on high doses of therapy
  • Participant has any of the following known untreated conditions; proliferative diabetic retinopathy, diabetic macular edema, macular degeneration or retinal vein occlusion.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
741 participants (actual)

Study arms

  • Experimental
    Roxadustat

    Participants will receive roxadustat tablets, administered orally 3 times weekly (TIW). Initial roxadustat dose will be based on the participant's average prescribed erythropoietin stimulating agent (ESA) dose in the 4 weeks (if on epoetin or darbepoetin or 8 weeks (if on Mircera®) prior to randomization. Dose adjustments will be permitted to maintain a hemoglobin (Hb) level of approximately 11 grams (g)/deciliter (dL). The maximum roxadustat dose is 3.0 milligrams (mg)/kilogram (kg) per dose or 400 mg per administration (whichever is lower).

    Drug: Roxadustat

  • Active comparator
    Epoetin Alfa

    Participants on hemodialysis (HD) will receive epoetin alfa, administered intravenously (IV) TIW and participants on home HD or peritoneal dialysis (PD) will receive epoetin alfa, administered subcutaneously (SC). Initial epoetin alfa dose will be based on the participant's average weekly prescribed ESA dose in 4 weeks prior to randomization if on epoetin or darbepoetin, and average monthly (4-week) prescribed ESA dose in 8 weeks prior to randomization if on Mircera®. In case of a change in route of administration from SC to IV (TIW), the initial dose of IV epoetin alfa will be determined by the investigator per local standard of care (SOC). Dose adjustments will follow the recommendations as per the approved country-specific product label (United States Package Insert \[USPI\] or Summary of Product Characteristics \[SmPC\]) or local SOC.

    Drug: Epoetin Alfa

Interventions

  • Epoetin alfa will be administered per dose and schedule specified in the arm.

  • Roxadustat will be administered per dose and schedule specified in the arm.

    Also known as: FG-4592

06

What researchers measure

Primary outcomes

  1. US (FDA) Submission: Mean Hb Change From Baseline to The Average Level During The Evaluation Period (Weeks 28 to 52), Regardless of Rescue Therapy

    Hb values under the influence of rescue therapy were not censored in the analysis. Rescue therapy for roxadustat treated participants was defined as recombinant erythropoietin or analogue (ESA) or red blood cell (RBC) transfusion, and rescue therapy for epoetin alfa treated participants was defined as RBC transfusion. Baseline Hb was defined the mean of up to 4 last central lab values prior to the first dose of study treatment. The intermittent missing Hb data was imputed for each treatment relying on non-missing data from all participants within each treatment group using the Monte Carlo Markov Chain (MCMC) imputation model, Monotone missing data were imputed by regression from its own treatment group.

    Time frame: Baseline (Day 1, Week 0), Weeks 28 to 52

  2. Ex-U.S. Submission: Mean Hb Change From Baseline to the Average Weeks 28 to 36, Without Having Received Rescue Therapy Within 6 Weeks Prior to and During This 8-Week Evaluation Period for Participants Enrolled Under the Original Protocol

    Hb values under the influence of rescue therapy were censored up to 6 weeks in the analysis. Rescue therapy for roxadustat treated participants was defined as recombinant erythropoietin or analogue (ESA) or RBC transfusion, and rescue therapy for epoetin alfa treated participants was defined as RBC transfusion. Baseline Hb was defined the mean of up to 4 last central lab values prior to the first dose of study treatment.

    Time frame: Baseline (Day 1, Week 0), Weeks 28 to 36

Secondary outcomes

  1. US (FDA Submission): Hb Responder Rate- Percentage of Participants With Mean Hb Level ≥10.0 g/dL Averaged Over Weeks 28 to 52, Regardless of Rescue Therapy

    Hb values under the influence of rescue therapy were not censored in the analysis. Rescue therapy for roxadustat treated participants was defined as recombinant erythropoietin or analogue (ESA) or RBC transfusion, and rescue therapy for epoetin alfa treated participants was defined as RBC transfusion.

    Time frame: Weeks 28 to 52

  2. Ex-U.S. Submission: Hb Responder Rate- Percentage of Participants With Mean Hb 10.0 to 12.0 g/dL Averaged Over Weeks 28 to 36, Censoring for Rescue Therapy

    Hb values under the influence of a rescue therapy were censored up to 6 weeks in the analysis. Rescue therapy for roxadustat treated participants was defined as recombinant erythropoietin or analogue (ESA) or RBC transfusion, and rescue therapy for epoetin alfa treated participants was defined as RBC transfusion.

    Time frame: Weeks 28 to 36

  3. Change From Baseline in Low-Density Lipoprotein (LDL) Cholesterol Averaged Over Weeks 12 to 28

    Baseline LDL Cholesterol was defined as the last available value prior to the first dose of study treatment.

    Time frame: Baseline (Day 1, Week 0), Weeks 12 to 28

  4. Change From Baseline in Hb Levels Averaged Over Weeks 18 to 24 Regardless of Rescue Therapy in Participants Whose Baseline High Sensitivity C-Reactive Protein (Hs-CRP)> Upper Limit of Normal (ULN)

    Hb values under the influence of rescue therapy were not censored in the analysis. Rescue therapy for roxadustat treated participants was defined as recombinant erythropoietin or analogue (ESA) or RBC transfusion, and rescue therapy for epoetin alfa treated participants was defined as RBC transfusion. Baseline Hb was defined the mean of up to 4 last central lab values prior to the first dose of study treatment. The intermittent missing Hb data was imputed for each treatment relying on non-missing data from all participants within each treatment group using the MCMC imputation model, Monotone missing data were imputed by regression from its own treatment group.

    Time frame: Baseline (Day 1, Week 0), Weeks 18 to 24

  5. Average Monthly IV Iron Use Per Patient-Exposure-Month (PEM) During Weeks 28 to 52

    Monthly iron use for each participant= Total IV iron in mg / \[(last dose date - first dose date of study medication in the period)+1\]/ 28.

    Time frame: Weeks 28 to 52

  6. Time to First RBC Transfusion

    Median time to event (weeks) was calculated using Kaplan Meier Survival Estimates.

    Time frame: Baseline (Day 1, Week 0) up to last dose of study drug (maximum treatment duration was 183.7 weeks for roxadustat and 180.4 weeks for epoetin alfa)

  7. Change From Baseline in Mean Arterial Pressure (MAP) Averaged Over Weeks 20 to 28

    Baseline MAP was defined as the mean of values obtained within 6 weeks prior to the first dose of study treatment.

    Time frame: Baseline (Day 1, Week 0), Weeks 20 to 28

  8. Time to First Exacerbation of Hypertension During Weeks 28 to 52

    An exacerbation of hypertension was defined as increase from baseline of ≥20 mmHg in systolic blood pressure (sBP) and sBP ≥170 mmHg or an increase from baseline of ≥15 mmHg in diastolic blood pressure (dBP) and dBP ≥100 mmHg. Median time to event (weeks) was calculated using Kaplan Meier Survival Estimates.

    Time frame: Weeks 28 to 52

  9. Change From Baseline in Short Form 36 (SF-36) Version 2 Physical Functioning Subscore and Vitality Subscore at Weeks 12 to 28

    The SF-36 V2 consists of 36 questions covering 8 health domains: physical functioning (10 items), bodily pain (2 items), role limitations due to physical problems (4 items), role limitations due to emotional problems (3 items), general health perceptions (5 items), mental health (5 items), social function (2 items), and vitality (4 items). The physical functioning subscore and vitality subscore are reported. Each scale was transformed into 0-100 score, with higher scores indicating better health status. Baseline score was defined as the last physical functioning value or vitality value, as applicable, prior to the first dose of study drug.

    Time frame: Baseline (Day 1, Week 0), Weeks 12 to 28

07

Results

Posted Oct 29, 2021

Participant flow

Participant flow — Overall Study
MilestoneRoxadustatEpoetin Alfa
Started370371
Received at least 1 dose of study drug370370
Completed127183
Not completed243188
Withdrew: Death7062
Withdrew: Withdrawal by subject4129
Withdrew: Kidney transplant3139
Withdrew: Physician decision3015
Withdrew: Adverse event279
Withdrew: Lost to follow-up63
Withdrew: Lack of efficacy61
Withdrew: Protocol violation40
Withdrew: Other than specified2830

Outcome measures

PrimaryUS (FDA) Submission: Mean Hb Change From Baseline to The Average Level During The Evaluation Period (Weeks 28 to 52), Regardless of Rescue Therapy

Hb values under the influence of rescue therapy were not censored in the analysis. Rescue therapy for roxadustat treated participants was defined as recombinant erythropoietin or analogue (ESA) or red blood cell (RBC) transfusion, and rescue therapy for epoetin alfa treated participants was defined as RBC transfusion. Baseline Hb was defined the mean of up to 4 last central lab values prior to the first dose of study treatment. The intermittent missing Hb data was imputed for each treatment relying on non-missing data from all participants within each treatment group using the Monte Carlo Markov Chain (MCMC) imputation model, Monotone missing data were imputed by regression from its own treatment group.

Time frame:
Baseline (Day 1, Week 0), Weeks 28 to 52
Reported as:
Mean · g/dL
US (FDA) Submission: Mean Hb Change From Baseline to The Average Level During The Evaluation Period (Weeks 28 to 52), Regardless of Rescue Therapy
g/dLRoxadustatEpoetin Alfa
Baseline10.30 ± 0.66110.31 ± 0.656
Change at Weeks 28 to 520.39 ± 0.934-0.09 ± 0.838
Statistical analysis
  • Roxadustat vs Epoetin Alfa · ANCOVA · p = <0.0001 · Ls mean difference: 0.48 · 95% CI 0.365 to 0.591ANCOVA with MI
PrimaryEx-U.S. Submission: Mean Hb Change From Baseline to the Average Weeks 28 to 36, Without Having Received Rescue Therapy Within 6 Weeks Prior to and During This 8-Week Evaluation Period for Participants Enrolled Under the Original Protocol

Hb values under the influence of rescue therapy were censored up to 6 weeks in the analysis. Rescue therapy for roxadustat treated participants was defined as recombinant erythropoietin or analogue (ESA) or RBC transfusion, and rescue therapy for epoetin alfa treated participants was defined as RBC transfusion. Baseline Hb was defined the mean of up to 4 last central lab values prior to the first dose of study treatment.

Time frame:
Baseline (Day 1, Week 0), Weeks 28 to 36
Reported as:
Mean · g/dL
Ex-U.S. Submission: Mean Hb Change From Baseline to the Average Weeks 28 to 36, Without Having Received Rescue Therapy Within 6 Weeks Prior to and During This 8-Week Evaluation Period for Participants Enrolled Under the Original Protocol
g/dLRoxadustatEpoetin Alfa
Baseline10.33 ± 0.63910.35 ± 0.614
Change at Weeks 28 to 360.54 ± 1.022-0.03 ± 0.897
Statistical analysis
  • Roxadustat vs Epoetin Alfa · Mixed Models Analysis · p = <0.0001 · Ls mean difference: 0.55 · 95% CI 0.404 to 0.687
SecondaryUS (FDA Submission): Hb Responder Rate- Percentage of Participants With Mean Hb Level ≥10.0 g/dL Averaged Over Weeks 28 to 52, Regardless of Rescue Therapy

Hb values under the influence of rescue therapy were not censored in the analysis. Rescue therapy for roxadustat treated participants was defined as recombinant erythropoietin or analogue (ESA) or RBC transfusion, and rescue therapy for epoetin alfa treated participants was defined as RBC transfusion.

Time frame:
Weeks 28 to 52
Reported as:
Number · percentage of participants
US (FDA Submission): Hb Responder Rate- Percentage of Participants With Mean Hb Level ≥10.0 g/dL Averaged Over Weeks 28 to 52, Regardless of Rescue Therapy
percentage of participantsRoxadustatEpoetin Alfa
US (FDA Submission): Hb Responder Rate- Percentage of Participants With Mean Hb Level ≥10.0 g/dL Averaged Over Weeks 28 to 52, Regardless of Rescue Therapy66.158.6
Statistical analysis
  • Roxadustat vs Epoetin Alfa · Responder rate difference: 7.6 · 95% CI 0.9 to 14.3
SecondaryEx-U.S. Submission: Hb Responder Rate- Percentage of Participants With Mean Hb 10.0 to 12.0 g/dL Averaged Over Weeks 28 to 36, Censoring for Rescue Therapy

Hb values under the influence of a rescue therapy were censored up to 6 weeks in the analysis. Rescue therapy for roxadustat treated participants was defined as recombinant erythropoietin or analogue (ESA) or RBC transfusion, and rescue therapy for epoetin alfa treated participants was defined as RBC transfusion.

Time frame:
Weeks 28 to 36
Reported as:
Number · percentage of participants
Ex-U.S. Submission: Hb Responder Rate- Percentage of Participants With Mean Hb 10.0 to 12.0 g/dL Averaged Over Weeks 28 to 36, Censoring for Rescue Therapy
percentage of participantsRoxadustatEpoetin Alfa
Ex-U.S. Submission: Hb Responder Rate- Percentage of Participants With Mean Hb 10.0 to 12.0 g/dL Averaged Over Weeks 28 to 36, Censoring for Rescue Therapy64.160.8
Statistical analysis
  • Roxadustat vs Epoetin Alfa · Responder rate difference: 2.7 · 95% CI -4.3 to 9.7
SecondaryChange From Baseline in Low-Density Lipoprotein (LDL) Cholesterol Averaged Over Weeks 12 to 28

Baseline LDL Cholesterol was defined as the last available value prior to the first dose of study treatment.

Time frame:
Baseline (Day 1, Week 0), Weeks 12 to 28
Reported as:
Mean · mg/dL
Change From Baseline in Low-Density Lipoprotein (LDL) Cholesterol Averaged Over Weeks 12 to 28
mg/dLRoxadustatEpoetin Alfa
Baseline84.53 ± 34.00984.45 ± 34.124
Change at Weeks 12 to 28-13.70 ± 23.0681.23 ± 22.389
Statistical analysis
  • Roxadustat vs Epoetin Alfa · Mixed Models Analysis · p = <0.0001 · Least square mean difference: -14.67 · 95% CI -17.640 to -11.695
SecondaryChange From Baseline in Hb Levels Averaged Over Weeks 18 to 24 Regardless of Rescue Therapy in Participants Whose Baseline High Sensitivity C-Reactive Protein (Hs-CRP)> Upper Limit of Normal (ULN)

Hb values under the influence of rescue therapy were not censored in the analysis. Rescue therapy for roxadustat treated participants was defined as recombinant erythropoietin or analogue (ESA) or RBC transfusion, and rescue therapy for epoetin alfa treated participants was defined as RBC transfusion. Baseline Hb was defined the mean of up to 4 last central lab values prior to the first dose of study treatment. The intermittent missing Hb data was imputed for each treatment relying on non-missing data from all participants within each treatment group using the MCMC imputation model, Monotone missing data were imputed by regression from its own treatment group.

Time frame:
Baseline (Day 1, Week 0), Weeks 18 to 24
Reported as:
Mean · g/dL
Change From Baseline in Hb Levels Averaged Over Weeks 18 to 24 Regardless of Rescue Therapy in Participants Whose Baseline High Sensitivity C-Reactive Protein (Hs-CRP)> Upper Limit of Normal (ULN)
g/dLRoxadustatEpoetin Alfa
Baseline10.30 ± 0.61610.24 ± 0.630
Change at Weeks 18-240.61 ± 1.020-0.03 ± 0.940
Statistical analysis
  • Roxadustat vs Epoetin Alfa · ANCOVA · p = <0.0001 (Threshold for significance at 0.05 level.) · Ls mean difference: 0.69 · 95% CI 0.503 to 0.869ANCOVA with MI
SecondaryAverage Monthly IV Iron Use Per Patient-Exposure-Month (PEM) During Weeks 28 to 52

Monthly iron use for each participant= Total IV iron in mg / \[(last dose date - first dose date of study medication in the period)+1\]/ 28.

Time frame:
Weeks 28 to 52
Reported as:
Mean · mg/PEM
Average Monthly IV Iron Use Per Patient-Exposure-Month (PEM) During Weeks 28 to 52
mg/PEMRoxadustatEpoetin Alfa
Average Monthly IV Iron Use Per Patient-Exposure-Month (PEM) During Weeks 28 to 5217.07 ± 53.37537.02 ± 106.778
Statistical analysis
  • Roxadustat vs Epoetin Alfa · Rank ANCOVA · p = 0.00091 (Threshold for significance at 0.05 level.) · Ls mean difference: -20.14 · 95% CI -33.842 to -6.445
SecondaryTime to First RBC Transfusion

Median time to event (weeks) was calculated using Kaplan Meier Survival Estimates.

Time frame:
Baseline (Day 1, Week 0) up to last dose of study drug (maximum treatment duration was 183.7 weeks for roxadustat and 180.4 weeks for epoetin alfa)
Reported as:
Median · weeks
Time to First RBC Transfusion
weeksRoxadustatEpoetin Alfa
Time to First RBC TransfusionNA (NA to NA)NA (NA to NA)
Statistical analysis
  • Roxadustat vs Epoetin Alfa · Cox Proportional Hazards model · p = 0.0337 · Hazard ratio (hr): 0.67 · 95% CI 0.466 to 0.970
SecondaryChange From Baseline in Mean Arterial Pressure (MAP) Averaged Over Weeks 20 to 28

Baseline MAP was defined as the mean of values obtained within 6 weeks prior to the first dose of study treatment.

Time frame:
Baseline (Day 1, Week 0), Weeks 20 to 28
Reported as:
Mean · millimeters of mercury (mmHg)
Change From Baseline in Mean Arterial Pressure (MAP) Averaged Over Weeks 20 to 28
millimeters of mercury (mmHg)RoxadustatEpoetin Alfa
Baseline101.41 ± 12.591100.34 ± 12.350
Change at Weeks 20 to 280.46 ± 10.9330.04 ± 10.489
Statistical analysis
  • Roxadustat vs Epoetin Alfa · Mixed Models Analysis · p = 0.3500 · Ls mean difference: 0.69 · 95% CI -0.760 to 2.142
SecondaryTime to First Exacerbation of Hypertension During Weeks 28 to 52

An exacerbation of hypertension was defined as increase from baseline of ≥20 mmHg in systolic blood pressure (sBP) and sBP ≥170 mmHg or an increase from baseline of ≥15 mmHg in diastolic blood pressure (dBP) and dBP ≥100 mmHg. Median time to event (weeks) was calculated using Kaplan Meier Survival Estimates.

Time frame:
Weeks 28 to 52
Reported as:
Median · weeks
Time to First Exacerbation of Hypertension During Weeks 28 to 52
weeksRoxadustatEpoetin Alfa
Time to First Exacerbation of Hypertension During Weeks 28 to 52NA (NA to NA)NA (NA to NA)
SecondaryChange From Baseline in Short Form 36 (SF-36) Version 2 Physical Functioning Subscore and Vitality Subscore at Weeks 12 to 28

The SF-36 V2 consists of 36 questions covering 8 health domains: physical functioning (10 items), bodily pain (2 items), role limitations due to physical problems (4 items), role limitations due to emotional problems (3 items), general health perceptions (5 items), mental health (5 items), social function (2 items), and vitality (4 items). The physical functioning subscore and vitality subscore are reported. Each scale was transformed into 0-100 score, with higher scores indicating better health status. Baseline score was defined as the last physical functioning value or vitality value, as applicable, prior to the first dose of study drug.

Time frame:
Baseline (Day 1, Week 0), Weeks 12 to 28
Reported as:
Mean · score on a scale
Change From Baseline in Short Form 36 (SF-36) Version 2 Physical Functioning Subscore and Vitality Subscore at Weeks 12 to 28
score on a scaleRoxadustatEpoetin Alfa
Physical functioning subscore: Baseline38.55 ± 11.20239.63 ± 11.368
Physical functioning subscore: Change at Weeks 12 to 28-0.15 ± 7.443-0.20 ± 6.380
Vitality subscore: Baseline51.65 ± 10.11151.27 ± 9.841
Vitality subscore: Change at Weeks 12 to 28-0.92 ± 7.0070.30 ± 7.041

Adverse events

Collected over Baseline (Day 1, Week 0) up to 28 days after the last dose of study drug (maximum treatment duration was 183.7 weeks for roxadustat and 180.4 weeks for epoetin alfa). Mortality presented is for the timeframe of Baseline (Day 1, Week 0) up to end of treatment (maximum treatment duration was 183.7 weeks for roxadustat and 180.4 weeks for epoetin alfa).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Roxadustat70/370 (18.9%)242/370 (65.4%)286/370 (77.3%)
Epoetin Alfa62/370 (16.8%)248/370 (67%)292/370 (78.9%)
Most frequent serious events
Showing 10 of 459
Most frequent serious events
EventRoxadustatEpoetin Alfa
PneumoniaInfections and infestations30/37039/370
Acute myocardial infarctionCardiac disorders31/37026/370
Fluid overloadMetabolism and nutrition disorders24/37027/370
Acute respiratory failureRespiratory, thoracic and mediastinal disorders15/37026/370
HyperkalaemiaMetabolism and nutrition disorders25/37025/370
Cardiac failure congestiveCardiac disorders23/37023/370
Cardiac arrestCardiac disorders20/37023/370
SepsisInfections and infestations18/37023/370
AnaemiaBlood and lymphatic system disorders16/37020/370
HypotensionVascular disorders18/37019/370
Most frequent other events
Showing 10 of 44
Most frequent other events
EventRoxadustatEpoetin Alfa
Arteriovenous fistula site complicationInjury, poisoning and procedural complications53/37071/370
DiarrhoeaGastrointestinal disorders54/37069/370
CoughRespiratory, thoracic and mediastinal disorders49/37069/370
DyspnoeaRespiratory, thoracic and mediastinal disorders56/37064/370
NauseaGastrointestinal disorders63/37060/370
VomitingGastrointestinal disorders60/37055/370
HypertensionVascular disorders59/37044/370
Pain in extremityMusculoskeletal and connective tissue disorders49/37058/370
FallInjury, poisoning and procedural complications36/37053/370
ConstipationGastrointestinal disorders44/37048/370

Baseline characteristics

The intent to treat (ITT) population included all randomized participants.

Age, Categorical
Age, Categorical(Participants)RoxadustatEpoetin AlfaTotal
<=18 years000
Between 18 and 65 years253246499
>=65 years117125242
Sex: Female, Male
Sex: Female, Male(Participants)RoxadustatEpoetin AlfaTotal
Female183156339
Male187215402
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)RoxadustatEpoetin AlfaTotal
Hispanic or Latino137129266
Not Hispanic or Latino233242475
Unknown or Not Reported000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)RoxadustatEpoetin AlfaTotal
Race — White165184349
Race — Black/African American158156314
Race — Asian211536
Race — American Indian/Alaskan Native10717
Race — Native Hawaiian or Other Pacific Islander134
Race — Other15621
08

Study locations

76 sites
  • Research Center
    Phoenix, Arizona 85012, United States
  • Research Center
    Pine Bluff, Arkansas 71603, United States
  • Research Center
    Chula Vista, California 91910, United States
  • Research Center
    Chula Vista, California 91915, United States
  • Research Center
    La Mesa, California 91942, United States
  • Research Center
    Long Beach, California 90806, United States
  • Research Center
    Long Beach, California 90813, United States
  • Research Center
    Los Angeles, California 90057, United States
  • Research Center
    Northridge, California 91324, United States
  • Research Center
    Ontario, California 91762, United States
  • Research Center
    Roseville, California 95661, United States
  • Research Center
    San Diego, California 92111, United States
  • Research Center
    San Dimas, California 91773, United States
  • Research Center
    San Gabriel, California 91776, United States
  • Research Center
    Whittier, California 90603, United States
  • Research Center
    Coral Springs, Florida 33071, United States
  • Research Center
    Lauderdale Lakes, Florida 33313, United States
  • Research Center
    Miami, Florida 33143, United States
  • Research Center
    Miami, Florida 33173, United States
  • Research Center
    Pembroke Pines, Florida 33028, United States
  • Research Center
    Tampa, Florida 33614, United States
  • Research Center
    Albany, Georgia 31701, United States
  • Research Center
    Meridian, Idaho 83642, United States
  • Research Center
    Shreveport, Louisiana 71101, United States
  • Research Center
    Springfield, Massachusetts 01107, United States
  • Research Center
    Detroit, Michigan 48202, United States
  • Research Center
    Detroit, Michigan 48236, United States
  • Research Center
    Pontiac, Michigan 48341, United States
  • Research Center
    Brookhaven, Mississippi 39601, United States
  • Research Center
    Columbus, Mississippi 39705, United States
  • Research Center
    Gulfport, Mississippi 39501, United States
  • Research Center
    Tupelo, Mississippi 38801, United States
  • Research Center
    Creve Coeur, Missouri 63141, United States
  • Research Center
    Kansas City, Missouri 64131, United States
  • Research Center
    Saint Ann, Missouri 63074, United States
  • Research Center
    Saint Louis, Missouri 63110, United States
  • Research Center
    Portsmouth, New Hampshire 03885, United States
  • Research Center
    North Brunswick, New Jersey 08902, United States
  • Research Center
    Albuquerque, New Mexico 87109, United States
  • Research Center
    Gallup, New Mexico 87301, United States
  • Research Center
    College Point, New York 11356, United States
  • Research Center
    New York, New York 11355, United States
  • Research Center
    Charlotte, North Carolina 28204, United States
  • Research Center
    Durham, North Carolina 27704, United States
  • Research Center
    Greenville, North Carolina 27834, United States
  • Research Center
    New Bern, North Carolina 28562, United States
  • Research Center
    Raleigh, North Carolina 27609, United States
  • Research Center
    Rocky Mount, North Carolina 27804, United States
  • Research Center
    Columbus, Ohio 43210, United States
  • Research Center
    Columbus, Ohio 43215, United States
  • Research Center
    Aiken, South Carolina 29803, United States
  • Research Center
    Columbia, South Carolina 29203, United States
  • Research Center
    Orangeburg, South Carolina 29118, United States
  • Research Center
    Sumter, South Carolina 29150, United States
  • Research Center
    Knoxville, Tennessee 37923, United States
  • Research Center
    Knoxville, Tennessee 37924, United States
  • Research Center
    Nashville, Tennessee 37205, United States
  • Research Center
    Nashville, Tennessee 37232, United States
  • Research Center
    Arlington, Texas 76015-2368, United States
  • Research Center
    Edinburg, Texas 78539, United States
  • Research Center
    Fort Worth, Texas 76104, United States
  • Research Center
    Fort Worth, Texas 76105, United States
  • Research Center
    Fort Worth, Texas 76112, United States
  • Research Center
    Fort Worth, Texas 76133, United States
  • Research Center
    Fort Worth, Texas 76164, United States
  • Research Center
    Grand Prairie, Texas 75050, United States
  • Research Center
    Houston, Texas 77054, United States
  • Research Center
    Houston, Texas 77099, United States
  • Research Center
    Lubbock, Texas 79430, United States
  • Research Center
    Mansfield, Texas 76063, United States
  • Research Center
    San Antonio, Texas 78202, United States
  • Research Center
    San Antonio, Texas 78221, United States
  • Research Center
    Alexandria, Virginia 20735, United States
  • Research Center
    Shorewood, Wisconsin 53226, United States
  • Research Center
    Caguas, 00725, Puerto Rico
  • Research Center
    San Juan, 00926, Puerto Rico
09

References and documents

Publications

  • Natale P, Palmer SC, Jaure A, Hodson EM, Ruospo M, Cooper TE, Hahn D, Saglimbene VM, Craig JC, Strippoli GF. Hypoxia-inducible factor stabilisers for the anaemia of chronic kidney disease. Cochrane Database Syst Rev. 2022 Aug 25;8(8):CD013751. doi: 10.1002/14651858.CD013751.pub2. PubMed 36005278 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2015 to primary completion in Sep 2018, 44 months.

Results were first posted in Oct 2021, 3 years 1 month after primary completion. A results delay was requested in Oct 2019.

Of 98 industry-sponsored phase 3 interventional studies under Anemia, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 49. This study's 44 months is above that.

Counting every sponsor, half of 149 studies reached it within 30 months; a quarter within 17 and three quarters within 51.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 22, 2014
First posted
Oct 24, 2014
StartActual
Jan 15, 2015
Primary completionActual
Sep 19, 2018
CompletionActual
Sep 19, 2018
Results delay requested
Oct 23, 2019
Results first posted
Oct 29, 2021
Last update
Oct 29, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 29, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02273726
Lead sponsor
FibroGen
Responsible party
Sponsor
First posted
Oct 24, 2014
Start date
Jan 15, 2015
Primary completion
Sep 19, 2018
Completion
Sep 19, 2018
Results posted
Oct 29, 2021
Last update
Oct 29, 2021

Study contacts

Meraf Eyassu
study director · FibroGen

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Roxadustat

Start the discussion